American Heart Journal
Volume 157, Issue 5 , Pages 883-888, May 2009

Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice

  • Jean-Jacques Goy, MD

      Affiliations

    • Service de cardiologie, Clinique Cecil, Lausanne, Switzerland
    • Corresponding Author InformationReprint requests: Jean-Jacques Goy, MD, Clinique Cecil, Avenue Ruchonnet 53, 1003 Lausanne, Switzerland.
  • ,
  • Philip Urban, MD

      Affiliations

    • Département Cardiovasculaire, Hôpital de la Tour, Meyrin, Switzerland
  • ,
  • Urs Kaufmann, MD

      Affiliations

    • Kardiologie Abteilung Herzzentrum, Beau-Site, Bern, Switzerland
  • ,
  • Charles Seydoux, MD

      Affiliations

    • Service de cardiologie, Clinique Cecil, Lausanne, Switzerland
  • ,
  • Edoardo De Benedetti, MD

      Affiliations

    • Département Cardiovasculaire, Hôpital de la Tour, Meyrin, Switzerland
  • ,
  • Alexandre Berger, MD

      Affiliations

    • Service de cardiologie, Clinique Cecil, Lausanne, Switzerland

Received 9 September 2008; accepted 7 February 2009. published online 26 March 2009.

Background

The long-term incidence of stent thrombosis (ST) and complications after sirolimus-eluting stents (SES) implantation is still a matter of debate.

Method

We conducted a systematic follow-up on the day of their 5-year SES implantation anniversary, in a series of consecutive real-world patients treated with a SES. The use of SES implantation was not restricted to “on-label” indications, and target lesions included in-stent restenosis, vein graft, left main stem locations, bifurcations, and long lesions. The Academic Research Consortium criteria were used for ST classification.

Results

Three hundred fifty consecutive patients were treated with SES between April and December 2002 in 3 Swiss hospitals. Mean age was 63 ± 6 years, 78% were men, 20% presented with acute coronary syndrome, and 19% were patients with diabetes. Five-year follow-up was obtained in 98% of eligible patients. Stent thrombosis had occurred in 12 patients (3.6%) [definite 6 (1.8%), probable 1 (0.3%) and possible 5 (1.5%)]. Eighty-one percent of the population was free of complications. Major adverse cardiac events occurred in 74 (21%) patients and were as follows: cardiac death 3%, noncardiac death 4%, myocardial infarction 2%, target lesion revascularization 8%, non–target lesion revascularization target vessel revascularization 3%, coronary artery bypass graft 2%. Non-TVR was performed in 8%.

Conclusion

Our data confirm the good long-term outcome of patients treated with SES. The incidence of complications and sub acute thrombosis at 5 years in routine clinical practice reproduces the results of prospective randomized trials.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-8703(09)00132-X

doi:10.1016/j.ahj.2009.02.007

American Heart Journal
Volume 157, Issue 5 , Pages 883-888, May 2009